28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.
September 2025 in “International Journal of Molecular Sciences” This review examined the potential effects of Kampo medicine Hangeshashinto on oral mucositis, highlighting that several natural products in its composition may inhibit intracellular AGEs, reduce inflammation from extracellular AGEs, and suppress cytotoxicity in stomatitis.
December 2013 in “American journal of transplantation” This case report describes a 27-year-old kidney transplant recipient with end stage renal failure who developed infections and adverse reactions, ultimately resolving with antiviral treatment targeting HHV6.
1461 citations
,
March 2004 in “Annals of oncology” This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.
505 citations
,
October 2011 in “Journal of clinical oncology” This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.